NCT03877263

Brief Summary

The purpose of this research study is to compare two specimen collection techniques (vaginal vs. endocervical swab) to screen for sexually transmitted infections in pregnant women. Either a physician or the patient may collect the vaginal specimen; the physician will collect the endocervical specimen during a standard-of-care pelvic exam. Each technique utilizes a specialized swab for specimen collection. We will used the Hologic Aptima C. trachomatis and N. gonorrhoeae detection assay to analyze both specimens. We hypothesize that the results from the physician-collected vaginal specimen will have equivalent outcomes those from the physician-collected endocervical specimen. If the techniques are equivalent for detecting infection, there may be an opportunity for cost saving and increased patient satisfaction with the vaginal technique, especially using patient-collected vaginal specimen collection.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
17

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 12, 2019

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

March 14, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 15, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 27, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 27, 2019

Completed
Last Updated

February 5, 2021

Status Verified

February 1, 2021

Enrollment Period

7 months

First QC Date

March 14, 2019

Last Update Submit

February 2, 2021

Conditions

Keywords

Chlamydia TrachomatisNeisseria gonorrhoeae

Outcome Measures

Primary Outcomes (1)

  • Compare the physician-collected vaginal swab outcomes to those from the physician-collected endocervical swab.

    Determine the rate of concordance for infection screening results between the physician collected vaginal and physician collected endocervical specimens in pregnant patients. Concordance will be defined as same results (whether positive or negative) on both methods.

    12 months

Secondary Outcomes (1)

  • Assess the costs of medical supplies used during pelvic examinations.

    12 months

Other Outcomes (1)

  • Patient satisfaction following specimen collection.

    12 months

Study Arms (2)

OB/GYN physician-collected vaginal swab

OTHER

Patients assigned to the physician-collected vaginal swab group will have their Vaginal swab for detection of STI collected by their obstetrics and gynecology (OB/GYN) physician. The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group.

Diagnostic Test: Endocervical swab for detection of STIDiagnostic Test: Vaginal swab for detection of STI

Patient-collected vaginal swab

OTHER

Patients assigned to the patient-collected vaginal swab group will self-collect the Vaginal swab for detection of sexually transmitted infection (STI). Patients who self-collect will receive instructions from their OB/GYN physician and in paper form. The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group.

Diagnostic Test: Endocervical swab for detection of STIDiagnostic Test: Vaginal swab for detection of STI

Interventions

After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.

OB/GYN physician-collected vaginal swabPatient-collected vaginal swab

After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays. We will then compare the results from a vaginal vs. endocervical specimens within and between the groups

OB/GYN physician-collected vaginal swabPatient-collected vaginal swab

Eligibility Criteria

Age16 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Pregnant \& receiving prenatal care at Doctors Hospital Women's Health Center
  • ≥16 years old
  • Able to understand \& consent to study participation
  • English speaking \& reading; if minor assent form is required, the parent or guardian must also be English speaking \& reading

You may not qualify if:

  • Females who are not pregnant.
  • \<16 years old.
  • Not english speaking \& reading; if minor assent form is required, the parent or guardian are not english speaking \& reading

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

OhioHealth Doctors Hospital

Columbus, Ohio, 43228, United States

Location

MeSH Terms

Conditions

Sexually Transmitted Diseases

Condition Hierarchy (Ancestors)

Communicable DiseasesInfectionsGenital DiseasesUrogenital DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Diana Topolnycky, DO

    Attending Physician

    STUDY CHAIR
  • Krista Jensen, DO

    Resident Physician

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
Patients agreeing to participate in the study will be randomized by visit into a study group in a 1:1 fashion. Patients who participate during both their initial and third trimester (of pregnancy) will be randomized twice to a study group. The randomization allocation schedule will be developed by biostatisticians from the OhioHealth Research \& Innovation Institute (OHRI), and will be hidden from the investigator until directly prior to enrollment to prevent bias. The clinical research coordinator will reveal the randomization allocation once patient is consented and enrolled into the study. Due to the nature of the study, we cannot completed mask the investigator from the study group while taking the vaginal swabs.
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 14, 2019

First Posted

March 15, 2019

Study Start

March 12, 2019

Primary Completion

September 27, 2019

Study Completion

September 27, 2019

Last Updated

February 5, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

All study data will be collected using study-specific data abstraction sheets/data collection tools (e.g., REDCap or Excel). Only institutional review board (IRB)-approved variables will be collected. Electronic files will be stored on a password-protected computer, and paper files will be stored in a secure facility with limited access (the offices of the OhioHealth Research Institute). Desktop or mobile computers used for research purposes will be password-protected and encrypted. Data transmitted over the internet or via email will be encrypted. All resulting data will be securely stored in electronic format according to OhioHealth policy; the data collection and storage processes will follow HIPAA guidelines in accordance to 45 Code of Federal Regulations (CFR) Part 160 \& 164, to protect both confidentiality and privacy of each participant. All protected health information (PHI) data will be released or destroyed per institution protocol.

Locations